We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

30 hedge funds and large institutions have $136M invested in Dianthus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

519% more capital invested

Capital invested by funds: $22M → $136M (+$114M)

65.02% more ownership

Funds ownership: 2.99% → 68.01% (+65%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

33% less funds holding

Funds holding: 45 → 30 (-15)

63% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 24

Holders
30
Holders Change
-15
Holders Change %
-33.33%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
9
Reduced
10
Closed
24
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$7K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.9M
2
FFM
Fairmount Funds Management
Pennsylvania
+$24.3M
3
5VM
5AM Venture Management
California
+$18.5M
4
APM
Avidity Partners Management
Texas
+$15.3M
5
VA
VR Adviser
New York
+$11.7M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$1.32M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$287K
3
HMC
Harvard Management Company
Massachusetts
-$252K
4
LSA
Leonteq Securities AG
Switzerland
-$152K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$134K
Name Holding Trade Value Shares
Change 		Change in
Stake
UB
51
UMB Bank
Missouri
– -$562 -46 Closed
AF
52
Allworth Financial
California
– -$285 -23 Closed
Barclays
53
Barclays
United Kingdom
– -$39 -3 Closed
1 2
3